CA2280913A1 — 2-piperazinone-1-acetic acid derivatives and their use
Assigned to Takeda Pharmaceutical Co Ltd · Expires 1998-09-11 · 28y expired
What this patent protects
The present invention provides compounds and medicines effective for prophylaxis and therapy of various diseases by controlling or inhibiting celladhesion. Especially, the compounds of this invention inhibits platelet aggregation action without remarkable elongation or hemorrhagi…
USPTO Abstract
The present invention provides compounds and medicines effective for prophylaxis and therapy of various diseases by controlling or inhibiting celladhesion. Especially, the compounds of this invention inhibits platelet aggregation action without remarkable elongation or hemorrhagic period and can be used as a safe and long-acting antithrombotic drug as compared with known substances showing the same activity. Compounds of this invention are piperazinones of formula (I), wherein the ring A is a basic heterocyclic group; the ring B is a nitrogen containing heterocyclic group or a cyclic hydrocarbon group; Y is CH2; R1 is H, OH, NH2 or a hydrocarbon group which may be bound through CO, S, SO or SO2; R2 is H or a hydrocarbon group; R3 is an optionally esterified or amidated carboxyl group; and D is a lower alkyl group substituted with an optionally esterified carboxyl group; or a salt thereof.
Drugs covered by this patent
- Bevyxxa (BETRIXABAN) · Portola Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.